Cédric Chauvignac

Title: Cédric Chauvignac: Innovator in Pharmaceutical Chemistry

Introduction

Cédric Chauvignac is a notable inventor based in Nogent-Sur-Marne, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target various health conditions. With a total of 2 patents, his work has the potential to impact the treatment of central nervous system diseases and other metabolic disorders.

Latest Patents

Chauvignac's latest patents include innovative compounds that serve as inhibitors of phosphodiesterase 10 (PDE10A). The first patent focuses on substituted 6,7-dialkoxy-3-isoquinolinol derivatives, which are useful in treating conditions such as psychosis, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain, and ophthalmic diseases. The second patent involves 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds that exhibit analgesic activity, along with therapeutic methods and compositions related to these compounds.

Career Highlights

Throughout his career, Cédric Chauvignac has worked with prominent companies in the pharmaceutical industry, including Allergan, Inc. and Exonhit Therapeutics, SA. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research and development in drug formulation.

Collaborations

Chauvignac has collaborated with esteemed colleagues such as Bertrand Leblond and John E Donello. These partnerships have fostered an environment of innovation and have led to the advancement of various therapeutic solutions.

Conclusion

Cédric Chauvignac's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for new treatments that address significant health challenges.